obesity

News

Pharma group slams Hims & Hers over Super Bowl GLP-1 ad

Partnership for Safe Medicines claims the Hims & Hers ad for compounded weight-loss drug semaglutide, due to run during the Super Bowl, is "reckless."

News

Martin Holst Lange, Novo Nordisk's head of development

Novo charts course ahead for CagriSema after lacklustre data

After its first phase 3 trial of obesity hope CagriSema left investors dissatisfied, Novo Nordisk has a plan to get the programme back on track.

News

Novo rises on Wegovy sales leap, but warns of a slowdown

Novo Nordisk is expecting greater competition and pricing pressure in the obesity and diabetes sectors this year.

News

Two more biotechs, Metsera and Maze, cross IPO finish line

Metsera and Maze Therapeutics have become the second and third biotechs to complete an IPO on the Nasdaq this year.

News

Veru shares plunge despite positive data in obesity trial

Veru's obesity candidate achieved the objective of preserving muscle in people taking weight-loss drug Wegovy, but its share price still fell sharply.

Patients